FDA Approves New Treatment for Rare Autoimmune Disease Dermatomyositis

The U.S. FDA has approved LISRAYA (brepocitinib), a once-daily pill, for adults with dermatomyositis (DM). This marks the first significant therapeutic advancement in decades for the rare systemic autoimmune disease, which causes progressive muscle weakness and extensive skin lesions. LISRAYA, a first-in-class TYK2/JAK1 inhibitor, is now immediately available in the U.S., offering a new option for patients.